Options
探討抗憂鬱劑在路易氏體失智症大鼠模型之效果
Date Issued
2020
Author(s)
鄭亭琳
Ting-Lin Zheng
Advisor
Abstract
路易氏體失智症(dementia with Lewy bodies, DLB)是臨床常見的失智症類別之一,盛行率僅次於阿茲海默症。其症狀以認知缺陷伴隨運動功能障礙為表現,此外也常出現精神相關症狀,如視幻覺與妄想等。DLB的病理特徵為α-synuclein (α-syn)與β-amyoid protein (Aβ)在腦中不正常堆疊導致路易氏體(Lewy bodies)沉積。此外,麩胺酸興奮性毒性在神經退化性疾病中是常見的病理機轉。α-syn的堆積會導致突觸前神經元的粒線體失去功能、增加氧化壓力,並加劇麩胺酸興奮性毒性。Aβ則會干擾突觸後神經元的細胞受體,使得細胞凋亡;並影響星狀膠細胞上麩胺酸轉運蛋白的再回收。先前研究指出三環抗憂鬱劑amitriptyline (AMI)能夠增加麩胺酸轉運蛋白(GLT-1)的表現量,促進麩胺酸的再回收。因此AMI可能有益於DLB。本研究目的在於探討AMI是否可以改善DLB的認知與運動缺陷,並且使用臨床失智症藥物rivastigmine (RIVA)作為正性控制組。 本研究以立體定位手術在雄性Wistar大鼠左側腦室與前額葉皮質分別注射α-syn基因載體 (10μg/10μl)與Aβ (5μg/2.5μl)以建立DLB之動物模型。而相同位置注射生理食鹽水作為假手術控制組。手術後每日施予腹腔注射AMI (10 mg/kg/ day, i.p)、RIVA(2 mg/kg/ day, i.p)或生理食鹽水(1 ml/kg/ day, i.p)。在治療第29天後以下列行為測試評估大鼠之運動與認知功能:開放空間試驗測量大鼠之運動功能、T型迷宮測量大鼠之工作記憶,以物件辨識試驗測量大鼠之辨識能力。在第38天將大鼠犧牲取腦進行免疫組織化學染色測量DLB之病理改變。 DLB疾病組在開放空間試驗與控制組無顯著差異,而AMI治療組與RIVA治療組相較於控制組與疾病組均有較低之活動量。所有組別在T型迷宮均比隨機猜測(50%)有較高的答對率。控制組大鼠在探索新物件的時間比探索舊物件的時間要顯著來的長,然而疾病組大鼠並無此現象。AMI治療組與RIVA治療組可以回復DLB大鼠的物件辨識功能。此結果推論DLB大鼠出現物件辨識的缺損,而非工作記憶的缺損。本研究中測量海馬迴及黑質紋狀系統的神經密度、α-syn的表現量及神經新生的數量。結果顯示DLB大鼠的黑質體緻密部及海馬迴CA1、CA3及齒狀回均出現神經退化之現象。AMI治療後可回復上述之神經缺陷,然而RIVA治療後並不影響DLB大鼠之病理表現。此外,DLB大鼠的齒狀回有較多的α-syn沉積且神經新生數量也顯著減少。α-syn之沉積只出現在海馬迴而在黑質紋狀系統中未觀察到。AMI治療組之大鼠其齒狀回雖然有α-syn之沉積,但AMI治療能夠恢復DLB大鼠神經新生的缺損。RIVA治療組雖能夠減少α-syn之沉積但無法恢復DLB大鼠神經新生的缺損。 上述研究結果顯示,DLB大鼠出現神經缺損並干擾認知功能,並減少神經新生之能力;AMI治療可以改善DLB大鼠的認知功能並減緩神經退化之現象,並增加神經新生。AMI治療不僅改善症狀還能減緩病理發展。因此AMI可能具有治療DLB的潛力。
Dementia with Lewy bodies (DLB) is a high prevalent neurodegenerative disorder, where motor and cognitive deficits are observed. The pathological feature of DLB is accumulation of Lewy bodies composed of α-synuclein (α-syn) and β-amyloid (Aβ) proteins in the brain. In addition, glutamate excitotoxicity have been reported in many neurodegenerative disease. α-Synuclein causes mitochondria dysfunction, increases oxidative stress in the presynaptic neuron, and deteriorates glutamate excitotoxicity. Aβ suppresses expression of glutamate transporter 1 (GLT-1) and causes apoptosis. Previous studies have shown that tricyclic antidepressant, for example amitriptyline (AMI), increases GLT-1 expression and promotes reuptake of glutamate, which may have beneficial effects for treatment DLB. The aim of the study was to measure the effects of AMI on behavioral and neuronal function in DLB. We used the cholinesterase inhibitor rivastigmine (RIVA), which often used in clinical for treating dementia, for positive control.For inducing DLB rat model, male Wistar rats were stereotaxically injected with recombinant adeno-associated viral vector with SNCA gene (10μg/10μl) and Aβ (5μg/2.5μl) into the left ventricle and prefrontal cortex, respectively. AMI (10 mg/kg/day, i.p.), RIVA(2 mg/kg/day, i.p.) or saline was injected intraperitonealy starting after the surgery. Starting from the 29th day, behavioral tests were performed to evaluate motor and cognitive functions. While staining of immunohistochemistry was used to evaluate pathological changes in the brain after behavioral tests we measured α-synuclein level, number of new born cells, and neuronal density in the hippocampus and in the nigrostriatal DAergic system. In the behavioral tests, DLB group showed no difference with control group in open field test. While AMI group and RIVA group have lower motor activity, compared with control and DLB groups. All the groups showed a higher percentage of correct responses than chance level (50%) in the T-maze test. Rats in the control group showed significant higher percentage of the time exploring novel object than exploring old object, while the DLB group did not show such phenomena. AMI group and RIVA group reversed the above deficits of DLB group. The present study indicated no deficit of working memory but impairment of object recognition in DLB rat model. Histologically DLB rats showed cell loss in the substantia nigra pars compacta and in the hippocampal CA1, CA3, and dentate gyrus (DG). Treatment with AMI reduced the above cell loss. But treatment with RIVA cannot reverse the phenomenon. Additionally, DLB rats showed lower number of new born cells and higher level of α-syn accumulation in the DG, but α-syn did not present in the nigrostriatal system. AMI treatment did not affect α-syn accumulation but recovered neurogenesis in the DG of DLB rats. While RIVA treatment can reverse the α-syn accumulation but did not affect the neurogenesis of DLB rats.In conclusion, the present study indicated that DLB shows neurological deficits, cognitive dysfuncion, and reduced neurogenesis. AMI improved the above deficits. The AMI treatment may target not only the symptoms but also the molecular pathology. Thus, AMI may have clinical potential for treating DLB.
Subjects
路易氏體失智症
認知缺陷
抗憂鬱劑
Dementia with Lewy bodies
cognitive impairment
antidepressant
Type
thesis
File(s)
No Thumbnail Available
Name
108CSMU5821002-001.zip
Size
4.54 MB
Format
Unknown
Checksum
(MD5):2c001baef616f844286bf1ce84c1094b